Australia's Curvebeam AI drops as Bell Potter cuts PT pending HiRise validation

Curvebeam AI

04/09/2025 06:38

Sept 4 (Reuters) - ** Shares of Australia's Curvebeam AI CVB.AX down as much as 10.7% at A$0.125

** Analysts at Bell Potter cut price target for the medical equipment manufacturer to A$0.15 from A$0.18; downgrades recommendation to "hold" from "buy"

** Bell Potter lowers FY26 revenue forecasts for co to be in line with its FY25 results

** Brokerage says Curvebeam AI's sales of HiRise scanner will remain restrained as product hasn't been validated yet for use with Stryker's SYK.N Mako robotic surgery system

** Had expected HiRise's validation from Stryker would be completed in Q4FY26, albeit currently there is no guarantee it will be finalised within the current fiscal, says Bell Potter

** CVB last down 7.1%, bringing YTD losses to 3.7%

 (Reporting by Keshav Singh Chundawat in Bengaluru)

 ((Keshav.SinghChundawat@thomsonreuters.com;))